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HCV infectionAbstract Introduction: HCV infection is responsible for liver ﬁbrosis. Fibroscan and diffusion
MRI have been proposed for non-invasive diagnosis and staging of hepatic ﬁbrosis.
Aim of the work: To assess the accuracy of diffusion MRI and/or ﬁbroscan in the diagnosis of liver
ﬁbrosis as compared to histopathology. Patients and methods pre-treatment laboratory work up,
ﬁbroscan, diffusion MRI of the liver and liver biopsy were done for 52 chronic HCV patients for
assessment of liver ﬁbrosis.
Results: There was a signiﬁcant difference between ADC values of F0 vs. F1, F3 and F4
(P= 0.008, 0.033 and 0.015) respectively, however no signiﬁcant differences were seen in the
ADC values between the other different ﬁbrosis stages. As regard the liver stiffness values, there
was a signiﬁcant difference between F1 and F3 (P= 0.001), F1 and F4 (P= 0.024) and between
F2 and F3 (P= 0.014).There was no signiﬁcant difference in the ADC values between (F0, F1,
F2) on one hand and (F3, F4) on the other hand (P= 0.387), while there was a highly signiﬁcant
difference in the liver stiffness values between both groups (p< 0.001).
Conclusions: Diffusion MRI can distinguish non-ﬁbrotic liver (F0) from advanced ﬁbrosis (F3 and
F4) but cannot be used to distinguish between the intermediate stages of ﬁbrosis-ﬁbroscan can
differentiate between (F0, F1, F2) and (F3, F4).
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Chronic hepatitis C virus (HCV) infection is responsible for
liver ﬁbrosis and may lead to potential long-term complications
such as liver cirrhosis and hepatocellular carcinoma (1).
Liver biopsy (LB) has traditionally been considered the
gold standard for pretreatment evaluation of liver ﬁbrosis in
patients with chronic hepatitis C (CHC). However, LB is an
invasive procedure with several shortcomings (intra- and
interobserver variability of histo-pathological interpretation,
sampling errors, high cost) and the risk of rare but potentially
life-threatening complications. In addition, LB is poorly
accepted by patients and it is not suitable for repeated
evaluation. Furthermore, the prevalence of CHC makes LB
unrealistic to be performed in all patients with this disease
who are candidates for antiviral therapy (2).
These limitations have stimulated the search for new non-
invasive approaches (3). Conventional cross-sectional imaging
techniques have limited capability to demonstrate liver ﬁbro-
sis. Ultrasound and CT-based modalities can demonstrate
the morphologic alterations of cirrhosis, but they are limited
in evaluating patients with earlier stages of liver disease (4,5).
In response to the rising prevalence of chronic liver
diseases, a number of imaging based methods including
ultrasonography-based transient elastography (ﬁbroscan),
computed tomography-based texture analysis and diverse
magnetic resonance (MR) imaging-based techniques have been
proposed for non-invasive diagnosis and grading of hepatic
ﬁbrosis across its entire spectrum of severity. MR imaging-
based techniques in current practice and in development for
noninvasive assessment of liver ﬁbrosis include conventional
contrast material-enhanced MR imaging, double contrast-
enhanced MR imaging, MR elastography, diffusion weighted
imaging and MR perfusion imaging (4).
There are several publications indicating the efﬁcacy of
quantitative apparent diffusion coefﬁcient (ADC) measure-
ment with diffusion weighted magnetic resonance imaging
(DW-MRI) in proving liver ﬁbrosis. Diffusion weighted imag-
ing is an advanced application of MRI used in evaluating the
microscopic structure of tissues. This imaging method relies on
quantiﬁcation of the diffusion of water molecules inside tis-
sues. Combined with other methods, this imaging modality
might be used in evaluating parenchymal tissue that has no
proven abnormalities with routine imaging modalities (6).
Liver ﬁbrosis results in extracellular accumulation of
collagen, glycosaminoglycans and proteoglycans that may
restrict the molecular diffusion of water, thus suggesting that
diffusion-weighted imaging (DWI) may be useful for assessing
ﬁbrosis (6).
The aim of the study was to assess the accuracy of
diffusion-weighted MRI and ﬁbroscan in the diagnosis of liver
ﬁbrosis as compared to histopathology of liver.
2. Patients and methods
2.1. Patients
This pilot study included 52 chronic HCV patients as diag-
nosed by seropositivity for HCV antibodies and HCV RNA
by PCR. They were referred for assessment prior to antiviral
therapy.Patients included were naı¨ve to antiviral therapy, their
ages ranged from 18 to 60 years. Patients with other liver
diseases, decompensated liver cirrhosis, hepatocellular carci-
noma, liver biopsy contraindication, those who were not ﬁt
for combined interferon and ribavirin treatment due to per-
sistent hematological abnormalities and those with BMI
>35 were excluded.
Patients were subjected to thorough history taking, clinical
examination, pre-treatment laboratory work, abdominal ultra-
sound, ﬁbroscan, MR diffusion and liver biopsy. The study
protocol was approved by the institutional review board and
written informed consent was given by each patient.
2.2. Liver stiffness measurement using ﬁbroscan
Liver stiffness was measured using the ultrasound TE
ﬁbroscan device (Echosens, Paris, France), which consists of
a 5-MHz ultrasound transducer probe mounted on the axis
of a vibrator. TE measures liver stiffness in a volume that
approximates a cylinder 1 cm wide and 4 cm long, between
25 and 65 mm below the skin surface.
The patient was lying in the dorsal decubitus with the right
arm in maximal abduction. The tip of the transducer was
covered with a drop of gel and measurements were taken in
the right lobe of the liver by placing the tip of the transducer
perpendicularly in the intercostal space.
The median value of ten successful acquisitions expressed
in kilopascal (kpa) and was kept as representative of liver
stiffness measurement.
– The clinical interpretation of TE depends on two important
parameters for results to be considered reliable:
(1) The interquartile range, which reﬂects the variability
of the validated measures, should not exceed 30% of
the median value.
(2) The success rate (the ratio of the number of successful
measurements to the total number of acquisitions)
should be at least 60%.
Liver stiffness measurements can be difﬁcult in obese
patients or with narrow intercostal space and impossible in
patients with ascites (7)
2.3. Ultrasound guided liver biopsy
It was performed after ﬁbroscan examination, using a semi-
automatic true-cut needle (16 G). Liver biopsy was ﬁxed in for-
malin and embedded in parafﬁn and all biopsy specimens were
analyzed by an experienced pathologist blinded to the result of
ﬁbroscan. All biopsy specimens were at least 15 mm lengths
and contain 6 portal tracts. Liver ﬁbrosis staging was evalu-
ated according to the METAVIR scoring system (8).
2.4. Diffusion-weighted MRI of the liver
MRI was performed using 1.5-T MRI scanner (Philips Intera)
equipped with phased-array torso surface coil.
Examination included axial T1 and T2 weighted images and
Diffusion MRI. Acquisition parameters were TR 4.4 ms, TE
2.1 ms, ﬂip angle 10, matrix size, 172 · 163, ﬁeld of view
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using respiratory triggered fat suppressed single-shot
echoplanar sequence that combined the two diffusion
(motion-probing) gradients before and after the 180 pulse
along with the three directions of section-select, phase-
encoding, and frequency-encoding and data acquisition with
EPI readout. Five increasing b values were applied as follows:
0, 200, 500, 700 and 1000 s/mm2.
ADC derives from linear regression analysis of the signal
intensity measured at each gradient application following the
equation: ADC = ln S/S0/(b0  b) where b is the gradient fac-
tor, S is the signal intensity after application of the diffusion
gradient, and S0 is the signal intensity at b= 0 s/mm
2.
Parallel imaging with generalized auto-calibrating partially
parallel acquisition (GRAPPA) with an acceleration factor of
two was applied to reduce the acquisition time.
2.4.1. Image analysis
After application of the DW sequence, we obtained a set of
images corresponding to each b value applied and an ADC
map, automatically calculated by special software. Quantita-
tive analysis of the ADCs of liver parenchyma was performed
by placing a circular region of interest (ROI) of standard
dimensions (1 cm2) on the ADC map in right liver segments
to avoid artifacts from abdominal wall and vascular motion.
ADC was automatically calculated. The ROI was placed
far from visible vascular and biliary structures and at least
1 cm far from the liver capsule and then transported on
corresponding ADC maps with a copy-paste operation.
Measurement was repeated three times, calculating mean
ADC value. It was decided to measure ADCs only on
good-quality images and in homogeneous areas of parench-
yma not affected by major artifacts due to chemical shift,
magnetic susceptibility, abdominal wall or vascular motion
(Fig. 1).
The time interval between MRI and histopathology ranges
from 27 to 42 days (mean 33.4 days).Fig. 1 44 years old female with chronic HCV cirrhosis (stage F4
on liver biopsy). Breath hold axial single shot echo-planar DWI
obtained with increasing b values. ADC map shows placement of
ROI in liver parenchyma. Calculated hepatic ADC was
1.08 · 103 mm2/s.3. Statistical analysis
Analysis of data was performed using SPSS 17 for Windows.
Description of quantitative variables was in the form of mean,
standard deviation (SD), median, 25th and 75th percentiles.
Description of qualitative variables was in the form of num-
bers (no.) and percents (%).
Data were explored for normality using Shapiro–Wilk test
of normality. The results indicated that some data were
normally distributed (parametric data) and some were not
normally distributed (nonparametric data), so suitable tests
were used accordingly.
Binary correlation was carried out by Pearson correlation
test or Spearman correlation test in case of nonparametric or
categorical ordinal variables.
A receiver operating characteristic (ROC) curve was
graphed to determine an appropriate ﬁbroscan score in pre-
dicting stage of liver ﬁbrosis that gives optimal sensitivity
and speciﬁcity.
The signiﬁcance of the results was assessed in the form of
P-value which is Signiﬁcant when P-value 60.05.
4. Results
Our study included ﬁfty-two patients, 37 (71.2%) were males
and 15 (28.8%) were females with mean age of (38.2 ± 8.37)
years.
Histopathological analysis and ﬁbrosis staging according to
the METAVIR scoring system revealed F0 in one patient
(1.9%), F1 in 17 patients (32.7%), F2 in 25 patients (48%),
F3 in 7 patients (13.5%) and F4 in 2 patients (3.8%).
There are statistically signiﬁcant differences in the mean
ADC values between F0 and F4, F0 and F3, F0 and F1 ﬁbrosis
stages (p value 0.015, 0.033 and 0.008 respectively), however no
signiﬁcant differences were seen in the ADC values between
other ﬁbrosis stages (Fig. 2).
Taking all ﬁbrosis groups, there was no signiﬁcant differ-
ence in the ADC values between the groups (p value 0.215).
As regards the ﬁbroscan (Fig. 3), the median (interquartile
range) stiffness values were 5.2 (5.2–5.2), 7.3 (6.10–8.90), 7.3
(6.0–10.35), 14.1 (10.0–29.30) and 35.8 (22.8–48.8) Kpa in
ﬁbrosis stages F0, F1, F2, F3, and F4 respectively. There
was a statistically signiﬁcant difference in the median stiffnessFig. 2 ADC values for different ﬁbrosis stages as detected by
biopsy.
Fig. 3 Fibroscan stiffness values for different ﬁbrosis stages as
detected by biopsy.
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and F3 (P= 0.014) and F2 and F4 (p value = 0.033) and by
comparing all ﬁbrosis groups, there was a statistically signiﬁ-
cant difference in the median stiffness of ﬁbroscan between
groups (p value 0.004) (Table 1).
When grouping the patients into those 6F2 and those >F2
the mean ± SD of ADC values was 1.14 ± 0.18, 1.09 ± 0.13
respectively and there was no signiﬁcant difference in the
ADC values between both groups (P= 0.387), while there was
a highly signiﬁcant difference in themedian (interquartile range)
ﬁbroscan stiffness between both groups 7.3 (6.1–9.30), 17.5
(11.3–31.15) respectively (p< 0.001) (Table 2).
ROC curves were used to analyze the usefulness of both
ADC values and liver stiffness measurements in predicting
>F2 ﬁbrosis stages.Table 1 P value between different ﬁbrosis stages (as regards
ADC by MRI diffusion and ﬁbroscan stiffness values).
P value
ADC by MRI diﬀusion Fibroscan stiﬀness
F0 vs. F4 .015* .221
F1 vs. F4 .924 .024*
F2 vs. F4 .994 .033*
F3 vs. F4 .579 .143
F0 vs. F3 .033* .127
F1 vs. F3 .351 .001
F2 vs. F3 .441 .014*
F0 vs. F2 .076 .257
F1 vs. F2 .889 .473
F0 vs. F1 .008 .147
Table 2 Comparison between ADC values and ﬁbroscan stiffness v
Histopatholo
6F2
ADC (s/mm2) mean ± SD 1.14± 0.18
Fibroscan (Kpa) stiﬀness median (IQR) 7.30 (6.1–9.3
ADC: apparent diffusion coefﬁcient, SD: standard deviation, IQR: interq
* p value signiﬁcant <0.05.5. Discussion
Diffusion-weighted imaging is an imaging modality imple-
mented to be used in abdominal diseases including diffuse liver
diseases. This modality takes approximately 3 min in addition
to a routine abdominal MRI and is a non-invasive procedure,
which does not require contrast material injection. Its advan-
tages include application without breath holding, repeatability
and relative cheapness. This modality may also be used in the
follow up of patients by making quantitative measurements on
ADC map constituted from diffusion images. Diffusion
includes movement behaviors of molecules in microscopic ran-
dom pattern and this movement is measured from mean diffu-
sion coefﬁcient. DW-MRI is sensitive to this movement that is
measured with ADC and water diffusion is measured with
ADC (9).
Huseyin et al., detected decreased apparent diffusion coefﬁ-
cient values in patients with hepatic ﬁbrosis compared to
patients without chronic hepatitis and there was a trend
toward decrease in hepatic apparent diffusion coefﬁcient
values with an increasing degree of ﬁbrosis (10).
Our results, in common with those of most studies, revealed
that there was a signiﬁcant difference in ADC values between
F0 and F4, F0 and F3, F0 and F1 ﬁbrosis stages, however,
there was substantial overlap in the ADC values of F1–F4
especially in the intermediate ﬁbrosis stages.
The ADC values of cirrhotic patients or patients with
advanced ﬁbrosis are lower than healthy persons as liver
ﬁbrosis results in extracellular accumulation of collagen,
glycosaminoglycans, and proteoglycans that may restrict the
molecular diffusion of water and this could explain lower
ADC values in those patients (6).
Moreover we could not specify a cutoff ADC value to dif-
ferentiate between patients 6F2 and patients >F2 or predict
advanced stage of ﬁbrosis.
In this respect it was found that diffusion weighted MRI
did not add information to conventional imaging methods or
that could replace core liver biopsy, which is the reference
standard for liver ﬁbrosis staging (11).
The results of several studies have shown that the ADC val-
ues of cirrhotic patients are lower than those of noncirrhotic
patients or of healthy volunteers (12), but the usefulness of
the ADC in evaluating the intermediate stages of ﬁbrosis
remains questionable.
Taouli et al. (13) assessed seven control subjects and 23
patients with hepatitis related liver disease. Although there
was a signiﬁcant difference in the ADC of the F0 and F1
groups compared with the ADC of the F2–F4 groups, there
was much overlap in the ADC values of individual patients
in each group.alues in patients 6F2 and patients >F2.
gy P value
>F2
1.09± 0.13 0.387
0) 17.50(11.3–31.15) <0.001*
uartile range.
MRI and ﬁbroscan vs. histopathology for assessment of liver ﬁbrosis 303Boulanger et al. (14) could not ﬁnd a difference between
ADC values and ﬁbrosis scores in 18 patients with hepatitis
C and 10 healthy volunteers.
Sandrasegaran et al. (11) showed a signiﬁcant difference in
the ADC values of nonﬁbrotic (F0) and cirrhotic (F4) patients.
However, it could not be used to reliably distinguish among
the intermediate stages of ﬁbrosis.
Regarding ﬁbroscan, our results showed that the median
stiffness values increased as the ﬁbrosis stage increased, with
some overlap between F0 and F1 ﬁbrosis stages.
There was a statistically signiﬁcant difference in the median
stiffness between F1 and F4 (P= 0.024), F1 and F3
(P= 0.001), F2 and F3 (P= 0.014) and F2 and F4
(p value = 0.033). No statistically signiﬁcant difference was
seen between F0 and F4 in our study as one patient only
was diagnosed as F0 by histopathology.
The difference between patients 6F2 and patients >F2 was
highly statistically signiﬁcant (P< 0.001).
Consistent with the study by Castera et al. (15), our
results reported a cutoff value of 9.95 kpa for the prediction
of advanced ﬁbrosis >F2 with Area under the ROC
curve (AUC= 0.889), P(< 0.001) sensitivity = 89%, and
speciﬁcity = 79%.
Lewin et al. (6) was able to discriminate F0–F1–F2 vs. F3–
F4, the best cut points were less than 1.21 s/mm2 for ADC and
greater than 12.9 kpa for transient elastography. Moreover
they compared DW MRI with ultrasound elastography
(Fibro-Scan, EchoSens) and Surrogate Serum Fibrosis
Markers (FibroTest, APRI, Forns index and Hyaluronate).
They found that DW MRI was equivalent to these tests in
detecting high stages (F3 and F4) of ﬁbrosis. On the other
hand, our results showed that ﬁbroscan can differentiate
between different ﬁbrosis stages with signiﬁcant difference
between patients 6F2 and patients >F2 while diffusion-
weighted MRI cannot be used to differentiate between both
groups of patients.
The disagreement between our study and the study done by
Lewin et al. (6) as regards the cutoff value of ADC values
between patients 6F2 and patients >F2 could be explained
by several factors. It was found that there was a signiﬁcant
relationship between the ADC values and necro-inﬂammation
scores. Besides ﬁbrosis, it seems that ADC values might also
reﬂect the intensity of inﬂammation or necrosis and decrease
with the alteration of the tissue structure. Steatosis could also
affect the ADC value. The disagreements sometimes found
between the DW MRI and liver biopsy results for ﬁbrosis
assessment could be explained by biopsy sampling errors.
Lastly, the small number of patients involved in our study
could have a role in the disagreement of results.
6. Conclusions
– MRI diffusion can be used to distinguish nonﬁbrotic liver
(F0) from cirrhotic liver (or from liver with advanced ﬁbro-
sis F3 and F4) but it cannot be used to distinguish between
the intermediate stages of ﬁbrosis.
– Fibroscan stiffness can differentiate between (F0, F1, F2)
and (F3, F4), and that ﬁbroscan remains one of the best
and reliable methods for assessment of ﬁbrosis in chronic
HCV patients.Conﬂict of interest
The authors declare that there are no conﬂicts of interest.
References
(1) Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur
RR, Magder LS, et al. The role of parenteral antischistosomal
therapy in the spread of hepatitis C virus in Egypt. Lancet
2000;355(9207):887–9.
(2) Trifan Anca, Stanciu Carol. Checkmate to liver biopsy in chronic
hepatitis C? World J Gastroenterol 2012;18(39):5514–20.
(3) Castera L. Transient elastography and other noninvasive tests to
assess hepatic ﬁbrosis in patients with viral hepatitis. J Viral
Hepat 2009;16(5):300–14. http://dx.doi.org/10.1111/j.1365-
2893.2009.01087.x, Epub 2009 February 25.
(4) Faria SC, Ganesan K, Mwangi I, Shiehmorteza M, Viamonte B,
Mazhar S, et al. MR imaging of liver ﬁbrosis: current state of the
art. Radiographics 2009;29(6):1615–35. http://dx.doi.org/10.1148/
rg.296095512.
(5) Burroughs Andrew K, Cholongitas Evangelos. Non-invasive tests
for liver ﬁbrosis: encouraging or discouraging results? J Hepatol
2007;46:751–5.
(6) Lewin M, Poujol-Robert A, Boe¨lle PY, Wendum D, Lasnier E,
Viallon M, et al. Diffusion-weighted magnetic resonance imaging
for the assessment of ﬁbrosis in chronic hepatitis C. Hepatology
2007;46(3):658–65.
(7) Castera L, Forns X, Alberti A. Non-invasive evaluation of liver
ﬁbrosis using transient elastography. J Hepatol 2008;48(5):835–47.
http://dx.doi.org/10.1016/j.jhep.2008.02.008, Epub 2008 February
26.
(8) The French METAVIR Cooperative Study Group. Intraobserver
and interobserver variations in liver biopsy interpretation in
patients with chronic hepatitis C. The French METAVIR
Cooperative Study Group. Hepatology. 1994;20(1 Pt 1): 15–20.
(9) Dogan Y, Soylu A, Kilickesmez O, Demirtas T, Kilickesmez KO,
Dogan SN, et al. The value of hepatic diffusion-weighted MR
imaging in demonstrating hepatic congestion secondary to
pulmonary hypertension. Cardiovasc Ultrasound 2010;21(8):28.
http://dx.doi.org/10.1186/1476-7120-8-28.
(10) Huseyin Ozkurt, Firat Keskiner, Ozan Karatag, Canan Alkim,
Erturk Sukru Mehmet, Muzaffer Basak. Diffusion weighted MRI
for hepatic ﬁbrosis: impact of b-value. Iran J Radiol
2014;11(1):e3555.
(11) Sandrasegaran K, Akisik FM, Lin C, Tahir B, Rajan J, Saxena R,
et al. Value of diffusion-weighted MRI for assessing liver ﬁbrosis
and cirrhosis. AJR Am J Roentgenol 2009;193(6):1556–60. http://
dx.doi.org/10.2214/AJR.09.2436.
(12) Girometti R, Furlan A, Bazzocchi M, Soldano F, Isola M,
Toniutto P, et al. Diffusion-weighted MRI in evaluating liver
ﬁbrosis: a feasibility study in cirrhotic patients. Radiol Med
2007;112(3):394–408, Epub 2007 April 20.
(13) Taouli B, Tolia AJ, Losada M, Babb JS, Chan ES, Bannan MA,
et al. Diffusion-weighted MRI for quantiﬁcation of liver ﬁbrosis:
preliminary experience. AJR Am J Roentgenol
2007;189(4):799–806.
(14) Boulanger Y, Amara M, Lepanto L, Beaudoin G, Nguyen BN,
Allaire G, et al. Diffusion-weighted MR imaging of the liver of
hepatitis C patients. NMR Biomed 2003;16(3):132–6.
(15) Caste´ra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E,
Haaser M, et al. Prospective comparison of transient elastogra-
phy, Fibrotest, APRI, and liver biopsy for the assessment of
ﬁbrosis in chronic hepatitis C. Gastroenterology 2005
Feb;128(2):343–50.
